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Probing the Sudlow Binding Site with Warfarin: How Does Gold 
Nanocluster Growth Alter Human Serum Albumin? 
B. A. Russell,a P. A. Mulheran,b D. J. S. Bircha and Y. Chena ? 
The search for new fluorescent molecules is vital to the advancement of molecular imaging and sensing for the benefit of 
medical and biological studies. One such class of new fluorescent molecule is fluorescent gold nanoclusters encapsulated in 
Human Serum Albumin (HSA-AuNC). In order to use this new fluorescent molecule as a sensor or fluorescent marker in 
biological imaging both in vitro and in vivo it is important to understand whether/how the proteins function is changed by 
the synthesis and presence of the gold nanoclusters inside the protein. Natural HSA acts as the main drug carrier in the blood 
stream, carrying a multitude of molecules in two major binding sites (Sudlow I and II). To test the effects of gold on the 
ability of HSA to act as a drug carrier we employed warfarin, an anticoagulant drug, as a fluorescent probe to detect changes 
between natural HSA and HSA-AuNCs. AuNCs are found to inhibit the take up of warfarin by HSA. Evidence for this is found 
from fluorescence spectral and lifetime measurements. Interestingly, the presence of warfarin bound to HSA also inhibits 
the formation of gold nanoclusters within protein. This research provides valuable insight into how protein function can 
change upon synthesis of AuNCs and how that will affect their use as a fluorescent probe. 
 
Introduction 
The search for new fluorescent molecules is vital to the 
advancement of molecular imaging and sensing for the benefit 
of medical and biological studies. Intensive research has been 
carried out in the development of nanoscale sensing and 
imaging using fluorescence based techniques based on newly 
developed fluorophores1-8. One such class of new fluorophore 
are fluorescent noble metal nanoclusters. A number of methods 
of creating these fluorophores have been developed; of interest 
to this study is the protein-directed synthesis of gold 
nanoclusters (AuNCs) using Human Serum Albumin (HSA) as the 
template protein. Much work has been carried out studying the 
fluorescent properties of protein encapsulated gold 
nanoclusters2,9-11. Interestingly they have been shown to 
possess unusually long fluorescence lifetimes in the 
microsecond regime, for a variety of protein, e.g., human serum 
albumin, bovine serum albumin and lysozyme, used to stabilize 
the AuNCs12. These nanoclusters have also been shown to be 
highly stable over a long period of time and highly resistant to 
photobleaching13. These properties add on their water 
solubility, biocompatibility, large stoke shift, sensitivity to metal 
ions as well as protein conformational changes14-16, making 
protein encapsulated AuNCs a potentially ideal probe for the 
tracking of long-term biological processes both in vitro and in 
vivo. To exploit this potential, it is essential to understand 
whether/how the protein function is changed by the synthesis 
and internal presence of the gold nanoclusters. Natural HSA acts 
as the main drug carrier in the blood stream carrying a 
multitude of molecules in two major binding sites (Sudlow I and 
II). Warfarin is traditionally used to thin the blood in patients 
with heart complications17. It is also a fluorescent molecule; 
with an absorption and emission maximum of 320nm and 
390nm respectively. Warfarin is a non-rigid molecule, as seen in 
Figure 1, transported around the body via HSA, binding to the 
major drug Sudlow I binding site17. Upon binding to the Sudlow 
ƐŝƚĞ ƚŚĞ ĚƌƵŐ ?Ɛ ĨůƵŽƌĞƐĐĞŶĐĞ ŝƐĞŶŚĂŶĐĞĚĚƵĞ ƚŽ ƚŚĞ ŵŽůĞĐƵůĞ
becoming stabilised, resulting in reduced energy dissipation due 
to non-radiative heat transfers to the surrounding solvent.  To 
test the effects of gold on the ability of HSA to act as a drug 
carrier, in this work, we employed warfarin as a fluorescent 
probe to detect changes between natural HSA and HSA-AuNCs 
by comparing the interaction of warfarin with natural HSA and 
HSA-AuNCs using steady state and time-resolved fluorescence 
spectroscopy.  
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Figure 1: Chemical structure of the warfarin molecule unbound to 
HSA. 
 
Materials and Methods  
The synthesis of HSA-AuNCs was carried out ƵƐŝŶŐ yŝĞ ?Ɛ
method18. All samples were then dialysed into PBS buffer 
solution with a concentration of 40µM, using 10kDa dialysis 
cassettes. All chemicals used were purchased from Sigma-
Aldrich. All dilutions of the sample were carried out using PBS 
buffer. Fluorescence emission spectra were measured on a 
Horiba Fluorolog 3. Fluorescence lifetimes were measured using 
the Time Correlated Single Photon Counting (TCSPC) technique 
on a Horiba Deltaflex. For all experiments a TAC range of 100ns 
was used and a NanoLED pulsed light source with an excitation 
wavelength of 303nm19. Analysis was carried out using DAS6 
software from Horiba. The method of fitting used was the non-
linear least-squares method using the following exponentials 
model to describe the decay kinetics: 
 ܫሺݐሻ ൌ  ? ܾ௜௡௜ୀଵ  ቀെ ௧ఛ೔ቁ    [1] 
 
tŚĞƌĞʏi are the decay times with amplitudes bi and ɇďi = 1. 
 
Equation [2] describes the normalised pre-exponential factors: 
 ߙ௜ ൌ  ௕೔ ? ௕೔೙೔సభ     [2] 
Results and discussion 
Figure 2 shows the normalised fluorescence spectra of warfarin 
(free and bound to HSA), HSA and HSA-AuNCs.  Free warfarin 
has an emission peak centred on 393nm under 320nm 
excitation, while warfarin bound to HSA has an emission peak 
at 370nm. The 340nm emission from HSA under 290nm 
excitation was due to fluorescent amino acid tryptophan in HSA. 
A red emission of 670nm and a shoulder around 440nm from 
HSA-AuNC under 290nm excitation was consistent with 
previous reports20.  The emission at 440nm from HSA-AuNCs 
has been reported before either as a result of intermediate, 
smaller AuNCs forming within the protein or the result of 
oxidised tryptophan present in the protein21-23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Fluorescence Emission Spectra of warfarin free in 
solution (pink), warfarin bound to HSA (green), tryptophan 
from HSA (red) and HSA-AuNCs (blue). 
 
To compare the binding of warfarin to HSA-AuNC and HSA, we 
introduced warfarin to both solutions in the same manner and 
ĐŽŵƉĂƌĞĚ ƚŚĞ ŝŶƚĞŶƐŝƚǇ ŽĨ ǁĂƌĨĂƌŝŶ ?Ɛ ĨůƵŽƌĞƐĐĞŶĐĞ ŝŶ ďŽƚŚ
solutions with warfarin alone in buffer solution. The HSA and 
HSA-AuNCs concentrations were kept the same at 40µM while 
increasing the concentration of warfarin from 0 to 15µM. All 
samples were excited at 320nm. The peak of warfarin 
fluorescence was observed at 372nm for warfarin with HSA and 
393nm for warfarin with HSA-AuNC or on its own, implying 
different bound state of the warfarin molecule. Figure 3 shows 
the fluorescence intensities of warfarin as a function of warfarin 
concentration.  
Fluorescence intensity of warfarin was enhanced by 6 times 
when 15µM of warfarin was mixed with HSA in comparison with 
that from the same warfarin solution alone. This compares well 
with previous studies undertaken with warfarin binding to HSA 
under the same conditions24, indicating the binding of warfarin 
with native HSA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Fluorescence intensity of warfarin emission against 
warfarin concentration in native HSA (red, emission 372nm). 
HSA-AuNCs (blue, emission 393nm) and pure warfarin solution 
(black, emission 393 nm) (excitation 320nm). 
In contrast to the significant increase of warfarin emission in 
Warfarin-HSA, no apparent change in the fluorescence intensity 
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of warfarin in HSA-AuNC solution was found. The relatively low 
fluorescence intensity and emission peak position at 393nm 
were comparable with free warfarin. The slightly higher initial 
intensities at low warfarin concentration were due to the 
overlapping of warfarin emission with the weak emission from 
HSA-AuNC around 440nm.  Nevertheless, the significant 
difference between the behaviour of warfarin with HSA and 
HSA-AuNC indicates much reduced binding of warfarin to HSA-
AuNC.  
The fluorescence lifetime of warfarin has been shown to be 
a powerful indicator of the local environment of the molecule 
in previous studies13. TCSPC measurements of the fluorescence 
lifetimes of warfarin were taken under the various conditions as 
used in above intensity studies. The fluorescence intensity 
decay curves were fitted to a multi-exponential model using 
non-linear least-squares analysis and the results are shown in 
Table 1. It was found that warfarin alone in solution had a very 
short, single lifetime of 0.12±0.01ns. This result compares well 
with previous publications25, and was explained by the molecule 
losing rotational and vibrational energy to the surrounding 
solvent26. Upon binding to pure HSA in solution the 
fluorescence decay was best fitted with 3 lifetime components. 
The shorter lifetime is no longer present indicating that there is 
no warfarin in solution. The longer lifetimes of 0.34±0.02, 
1.75±0.06ns and 6.63±0.15ns can be explained by the stability 
the warfarin gains as a result of binding to the HSA protein and 
are again consistent with previous reports27. 
 
Sample Warfarin HSA-War HSA-AuNCs 
+ War 
ʏ1(ns) 0.12 
± 0.01 
0.34 
±0.02 
0.16 
±0.02 
ʏ2(ns) - 1.75 
±0.06 
1.86 
±0.31 
ʏ3(ns) - 6.63 
±0.15 
4.98 
±0.28 
b1 0.026 
±0.001 
0.054 
±0.001 
0.169 
±0.001 
b2  - 0.036 
±0.001 
0.094 
±0.001 
b3  - 0.002 
±0.001 
0.030 
±0.001 
ɲ1 1.00 0.58 0.93 
ɲ2 - 0.39 0.05 
ɲ3 - 0.03 0.02 
ʖ2 1.37 1.30 1.30 
 
Table 1: Lifetime analyse data from warfarin alone, warfarin 
with HSA and warfarin with HSA-AuNC. 
Interestingly warfarin fluorescence lifetimes had different 
values when in solution with HSA-AuNCs. The decay is again 
best described by a 3-exponential function with similar lifetime 
values of 0.16±0.02ns, 1.86±0.31ns and 4.98±0.28ns. However 
ƚŚĞƐŚŽƌƚĞƐƚůŝĨĞƚŝŵĞ ?ʏ1 is the dominant fluorescent species with 
ĂĐŽƌƌĞƐƉŽŶĚŝŶŐɲ1 value of 0.93. This short lifetime compares 
well with the lifetime of free warfarin. This result suggests that 
the majority of warfarin molecules do not bind to HSA when 
AuNCs are present in HSA. The existence of longer lifetime 
components is possibly due to warfarin binding to free HSA in 
solution which does not contain AuNCs26.  
In order to show that most of the warfarin still remains 
unbound in solution with HSA-AuNCs, additional native HSA was 
added to the solution. Any large increases in warfarin 
fluorescence intensity can be attributed to the binding of free 
warfarin to the native HSA. The fluorescence intensity of 
warfarin was seen to increase dramatically upon adding HSA to 
the HSA-AuNCs + warfarin solution, as shown in Figure 4. 
Fluorescence anisotropy decay studies proved to be 
inconclusive in comparison to the fluorescence intensity, 
spectral and lifetime evidence. In order to rule out the influence 
of intrinsic fluorescence from HSA, control tests were carried 
out by adding further amounts of HSA to HSA-AuNCs (without 
warfarin) and to HSA with warfarin already attached. It can be 
seen that the fluorescence intensity of warfarin remains stable 
ǁŝƚŚĂĚĚŝƚŝŽŶĂů,^ƵƉƚŽ ? ?ʅM and are close to the intensity 
from HSA-AuNCs  Wwarfarin solution with higher additional HSA 
concentrations. It was also found that the emission at 393nm 
remained low in HSA-AuNCs solution without warfarin with a 
very small increase in the intensity at high HSA concentration 
due to the intrinsic fluorescence of HSA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Fluorescence intensity of warfarin upon adding 
additional free HSA to solution of HSA-AuNCs (40µM) + 
warfarin (10µM) (red), as well as solution of HSA 
(40µMwarfarin (10µM) (blue) and HSA-AuNCs (40µM) solution 
(black) as references.  
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This suggests that: firstly, in the case of HSA-warfarin, most 
warfarin is bound to HSA and the increase found here is due to 
intrinsic HSA emission; secondly, the large fluorescence 
intensity increase when adding additional HSA to HSA-AuNCs + 
warfarin is not due to intrinsic HSA, but binding of free warfarin 
to newly added HSA; thirdly, the final emission intensity of HSA 
+ warfarin and HSA-AuNC + warfarin +HSA are very close 
suggesting that all previously unbound  warfarin in the HSA-
AuNC solution was bound to HSA. These findings confirm that 
warfarin in HSA-AuNC solution is free and unbound in solution 
and the previous low fluorescence intensity of warfarin was due 
to a lack of warfarin binding rather than quenching processes or 
alterations to the fluorescence nature of warfarin. It is clear that 
the existence of AuNCs in HSA affects the binding of warfarin to 
protein. This may be due to the nucleation site of AuNCs being 
in close proximity to the warfarin binding site20. 
 If this were true, the growth of AuNC in HSA would also be 
affected by the binding of warfarin with HSA. To test this idea, 
we synthesized AuNCs in HSA with pre-bound warfarin in 
comparison with native HSA. The formation of AuNCs was 
investigated by monitoring the fluorescence emission from 
AuNCs. Figure 5 shows the emission of spectra taken after 0, 1 
and 6hr of synthesis. It can be seen that initially there was a 
strong emission at 440nm, implying a large amount of 
intermediate product (e.g., small gold clusters), while 
fluorescence at 640nm dominated the spectrum after 6hrs, 
indicating the formation of large AuNCs.  
  Figure 6 depicts the time evolution of these two peaks from 
solution with HSA and HSA with pre-bound warfarin. In the case 
of native HSA, the emission at 440nm decreases overtime, while 
the emission at 640nm increases. This indicates the decrease of 
intermediate products as them merging into larger gold 
nanoclusters, as reported before28.  
The lack of fluorescence at either 440nm or 640nm for the 
synthesis using HSA with pre-bound warfarin indicates that 
neither intermediate products nor large AuNCs are present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Fluorescence Emission spectra of HSA-AuNC taking at 
different periods during synthesis; 0 hr ʹ red, 1 hr ʹ black, and 
6 hrs - green (excitation 280nm). 
Figure 6: Time evolution of fluorescence intensity of emissions 
at 440nm and 640nm from HSA-AuNC (red and blue) and HSA-
warfarin-AuNC (black and green) during the synthesis 
(excitation 280nm).  
 
It is thus clear that the bound warfarin affects the ability of HSA 
to interact and bind with the gold salt present in solution during 
synthesis.   
 From previous molecular dynamics simulation work20 it was 
seen that Au atoms interacted with the Sudlow I binding site for 
a short amount of time before transporting to a final AuNC 
nucleation site. Tyrosine has been shown to play a critical factor 
in the reduction of gold salt; of which an accessible residue 
resides within the Sudlow I binding site. It is possible that this 
Tyrosine residue (Position 149 for BSA, position 148 for HSA in 
the polypeptide chain) plays a critical role in the reduction of 
the gold salt molecules during synthesis.  
Warfarin binding to the amino acid residues: arginine, lysine 
and may block the accessibility of this tyrosine molecule to gold 
salt while it is bound to HSA. This explains the lack of small 
intermediates formation in the case of HSA with pre-bound 
warfarin.  This also explains why warfarin cannot bind to HSA-
AuNCs; it is possible that excess gold salt or by-products of the 
reduction reaction block the Sudlow I binding site. Chloride ions 
have been previously reported to have a high affinity for 
histidine29. The Chlorine bond to the positively charged nitrogen 
centres of these residues through hydrogen bonding. If the 
leftover chlorine ions from the gold salt reduction bind to the 
above residues present in the Sudlow I binding site access could 
be physically hindered for warfarin. Due to the very low 
concentration of excess chlorine ions it is not possible that 
protein conformation is drastically altered. It is suggested that 
the warfarin binding affinity decreases with chlorine ion 
concentration increase due to both competing for the same 
binding site30. The presence of chlorine ions would also change 
the steric attraction between warfarin and the Sudlow I binding 
site lowering the overall binding affinity. Another factor to 
consider is the formation of dimers and aggregates of protein 
after AuNC nucleation in HSA; the formation of aggregates may 
physically block Warfarin to access binding at Sudlow site I. 
Alternatively increases to the negative surface charge of HSA 
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upon AuNC formation may be responsible for the lack of 
warfarin-HSA binding. Further studies are required for revealing 
the detail mechanisms. 
Conclusions 
We have successfully used warfarin as a fluorescent probe to 
ƐƚƵĚǇƚŚĞŝŶĨůƵĞŶĐĞŽĨƵEƐŝŶ,^ŽŶƉƌŽƚĞŝŶ ?ƐĨƵŶĐƚŝŽŶĂůŝƚǇ ?
It was found that warfarin was unable to bind to HSA-AuNC, 
implying the Sudlow I binding site of HSA is directly affected by 
the presence of AuNCs. It was found that AuNCs cannot be 
formed in HSA with a warfarin molecule already bound. This 
suggests that the Sudlow I binding site may have an important 
role in the gold atom transport and cluster nucleation. We 
suggest that the tyrosine present in the Sudlow I binding site 
plays a critical role in the reduction of gold salt and subsequent 
formation of AuNCs. These findings should be taken into 
consideration in the future if protein-encapsulated proteins are 
to be used as fluorescent probes in the study of biological 
process where the Sudlow I binding is important. It is not clear 
if other molecules binding to the Sudlow I binding sites of HSA 
are affected by the presence of AuNCs and further studies 
would be required.  
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